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Low-density lipoprotein cholesterol 
and survival in pulmonary arterial 
hypertension
Grzegorz Kopeć1, Marcin Waligóra1, Anna Tyrka1, Kamil Jonas1, Michael J. Pencina2, 
Tomasz Zdrojewski3,4, Deddo Moertl5, Jakub Stokwiszewski4, Paweł Zagożdżon6 & 
Piotr Podolec1
Low-density lipoprotein cholesterol(LDL-C) is a well established metabolic marker of cardiovascular 
risk, however, its role in pulmonary arterial hypertension (PAH) has not been determined. Therefore 
we assessed whether LDL-C levels are altered in PAH patients, if they are associated with survival in 
this group and whether pulmonary hypertension (PH) reversal can influence LDL-C levels. Consecutive 
46 PAH males and 94 females were age matched with a representative sample of 1168 males and 
1245 females, respectively. Cox regression models were used to assess the association between 
LDL-C and mortality. The effect of PH reversal on LDL-C levels was assessed in 34 patients with 
chronic thromboembolic pulmonary hypertension (CTEPH) undergoing invasive treatment. LDL-C 
was lower in both PAH (2.6 ± 0.8 mmol/l) and CTEPH (2.7 ± 0.7 mmol/l) patients when compared 
to controls (3.2 ± 1.1 mmol/l, p < 0.001). In PAH patients lower LDL-C significantly predicted death 
(HR:0.44/1 mmol/l, 95%CI:0.26–0.74, p = 0.002) after a median follow-up time of 33(21–36) months. In 
the CTEPH group, LDL-C increased (from 2.6[2.1–3.2] to 4.0[2.8–4.9]mmol/l, p = 0.01) in patients with 
PH reversal but remained unchanged in other patients (2.4[2.2–2.7] vs 2.3[2.1–2.5]mmol/l, p = 0.51). We 
concluded that LDL-C level is low in patients with PAH and is associated with an increased risk of death. 
Reversal of PH increases LDL-C levels.
Pulmonary arterial hypertension (PAH) is a severe disease with high mortality1–3. Till now some prognostic fac-
tors, including clinical signs of right heart failure, impaired exercise capacity, right ventricular dysfunction and 
impaired pulmonary hemodynamics have been associated with poor outcome1–3. Recently, more focus has been 
placed on the prognostic role of alterations in the glucose and lipid metabolism4–7. Low high-density lipoprotein 
cholesterol (HDL-C) in PAH patients has been associated with worse clinical outcomes and higher mortality. 
This finding was independent of cardiovascular risk factors, insulin resistance and severity of the disease. It was 
hypothesized that anti-inflammatory properties of HDL-C, its ability to enhance prostacyclin half-life and its 
protective role in endothelium could explain its impact on prognosis in PAH4–7.
Low-density lipoprotein cholesterol (LDL-C) is an established marker of cardiovascular risk8. While high 
LDL-C levels are associated with worse prognosis in the general population, there are some populations with 
chronic diseases including diabetes, heart failure9, chronic kidney disease10,11 and rheumatoid arthritis12,13 where 
low LDL-C levels have been linked to increased mortality.
In PAH, low LDL-C levels might accelerate disease progression by several mechanisms including exacerbation 
of inflammation14,15 and direct effects on the arterial wall16. In fact, we have recently shown that low LDL-C levels 
are associated with increased stiffness of pulmonary arteries16. Conversely, as observed in other diseases, chronic 
inflammation14,15, hepatic congestion17 and low nutritional status18,19 might be associated with reduced LDL-C 
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levels in individuals with PAH. If this is true, clinical improvement of a patient could lead to normalization of 
LDL-C levels. However, data regarding the role of LDL-C in PAH is scarce.
We therefore investigated whether LDL-C levels are altered in PAH patients and whether they are associated 
with survival in this group. Additionally, we evaluated whether reversal of pulmonary hypertension (PH) can 
influence LDL-C levels. For this purpose we studied another group of patients with chronic thromboembolic 
pulmonary hypertension (CTEPH) which is the only potentially curable type of PH.
Results
PAH population. The PAH sample included 140 patients. The majority (n = 109; 78%) of them were newly 
diagnosed and treatment naive at inclusion. The remaining patients were already on monotherapy with sildenafil 
(n = 14; 10%), endothelin receptor antagonists (n = 13; 9.3%), or prostanoids (n = 2; 1.4%) or on combination 
therapy with endothelin receptor antagonists and sildenafil (n = 2, 1.4%). At enrollment 15 patients used atorvas-
tatin at mean dose of 20.7 ± 8.8 mg and 13 patients used simvastatin at mean dose of 17.9 ± 4.3 mg. During the 
observation period the doses did not changed significantly, respectively 18.7 ± 11.3 mg for atorvastatin (p = 0.59) 
and 15.4 ± 12.3 mg (p = 0.5) for simvastatin. Diabetes was present in 11 (7.8%) patients, hypertension in 35 (25%) 
patients, obesity in 18 (13%) patients and overweight in 38 (27%) patients. Eight (5.7%) patients were active 
smokers, no patient declared alcohol abuse. The mean creatinine level was 85.9 ± 42.9 μ mol/l, mean aspartate 
transaminase (AST) 28.4 ± 12.8 U/l, and mean alanine transaminase (ALT) 29.7 ± 29.9 U/l. Seventeen (12%) 
patients were actively treated due to thyroid function abnormalities, however at enrollment all patients had thy-
roid stimulating hormone (TSH) values within normal range. Twenty two (16%) patients had higher education 
and 38 (27%) patients were still working full-time at enrollment. As most (n = 99; 70.7%) patients were in World 
Health Organization functional class (WHO-FC) III their daily activities were limited. The patients were not 
advised any specific dietary recommendations. Clinical, demographic, laboratory and hemodynamic data of PAH 
population are presented in Table 1.
Comparison with age and sex-matched controls. LDL-C was stable during 3 month follow-up: 
2.57 ± 0.88 mmol/l at enrollment and 2.59 ± 0.98 mmol/l at follow-up; p = 0.67. As compared to controls it was 
lower in PAH women, men and patients who did not use statins (Table 2). LDL-C levels were similar in the 
subgroups of idiopathic PAH (IPAH), PAH associated with connective tissue disease (CTD-PAH), and PAH 
associated with congenital heart disease (CHD-PAH) (2.4[1.7–3.0] vs 2.8 [2.1–3.6] vs and 2.6 [2.1–3.0] mmol/l, 
respectively, p = 0.83). Sex–specific comparisons of other cardiovascular risk factors between PAH patients and 
age-matched controls are presented in Table 2.
Clinical characteristics and LDL-C levels. The associations of age, sex, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), creatinine, cardiovascular risk factors, markers of PAH severity and LDL-C 
levels are presented in Table 3. In univariate linear regression analysis triglycerides (TG), WHO-FC class and sex 
were associated with LDL-C level, however in a multiple regression model [R2 = 0.26, F(2, 86) = 15.2, p < 0.001] 
including all variables given in Table 3 significant relationship with LDL-C remained only for TG (beta coefficient 
PAH group (n = 140)
Age (y) 46 [28.0–62.0]
Sex (male) 46 (32%)
PAH etiology
 IPAH 63 (45%)
 CTD-PAH 17 (12%)
 CHD-PAH 60 (43%)
WHO FC (II/III/IV) 19 (13.6%)/99 (70.7%)/22 (15.7%)
mPAP (mmHg) 52.0 [41.0–71.0]
RAP (mmHg) 7.0 [3.0–9.0]
PAWP (mmHg) 9.0 [6.0–12.0]
Ao mean pressure (mmHg) 92.0 ± 14.2
CO (l/min) 3.1 [2.3–4.3]
CI (l/min/m2) 1.75 [1.4–2.4]
PVR (WU) 15.7 [9.9–22.5]
NT-proBNP (pg/ml) 619.4 [183.2–2229.0]
6MWD (m) 321.3 ± 133.3
Table 1.  Characteristics of patients with pulmonary arterial hypertension. 6-MWD – 6-minute walk 
distance, Ao – aorta, CHD-PAH – pulmonary arterial hypertension associated with congenital heart disease,  
CI – cardiac index, CO – cardiac output, CTD-PAH – pulmonary arterial hypertension associated with 
connective tissue disease, IPAH – idiopathic pulmonary arterial hypertension, mPAP – mean pulmonary 
arterial pressure, NT-proBNP – N-terminal pro-brain natriuretic peptide, PAH – pulmonary arterial 
hypertension, PAWP – pulmonary artery wedge pressure, PVR – pulmonary vascular resistance, RAP –  
right atrial pressure, WHO-FC – World Health Organization functional class.
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PAH (n = 140) Controls (n = 2413) p-value
f (n = 94) m (n = 46) f (n = 1245) m (n = 1168) f m
Age (years) 43.6 ± 17.2 41.6 ± 16.4 44.8 ± 27.1 42.9 ± 24.0 0.49 0.56
BMI (kg/m2) 23.8 ± 4.16 24.9 ± 5.2 25.9 ± 7.3 27.1 ± 6.7 < 0.001 0.002
SBP (mmHg) 109.2 ± 16.9 108.9 ± 16.6 130.1 ± 30.0 136.7 ± 26.9 < 0.0001 < 0.0001
DBP (mmHg) 70.3 ± 10.4 70.0 ± 11.3 80.6 ± 13.1 82.4 ± 15.7 < 0.0001 < 0.0001
LDL-C (mmol/l) 2.6 ± 0.8 2.3 ± 0.9 3.2 ± 1.1 3.2 ± 1.2 < 0.0001 < 0.0001
LDL-C (mmol/l)[without statins]* 2.6 ± 0.8 2.3 ± 0.8 3.3 ± 1.1 3.3 ± 1.2 < 0.0001 < 0.0001
HDL-C (mmol/l) 1.3 ± 0.4 1.1 ± 0.3 1.4 ± 0.4 1.2 ± 0.5 0.02 0.18
TG (mmol/l) 1.3 ± 0.7 1.3 ± 0.8 1.1 ± 0.8 1.6 ± 1.6 0.054 0.19
Glucose (mmol/l) 5.4 ± 1.7 5.5 ± 0.9 5.0 ± 1.0 5.3 ± 1.6 0.0003  0.49
Diabetes 10% 3% 5.9% 4.6% 0.17 0.88
Statin use 19% 21% 11.9% 11.2% 0.06 0.07
Hypertension 21% 32% 25% 28.2% 0.46 0.69
Active smoker 4.9% 7.2% 27.1% 35.6% < 0.0001 0.0001
Table 2.  Cardiovascular risk factors in patients with pulmonary arterial hypertension and age and sex-
matched general population. BMI – body mass index, DBP – diastolic blood pressure, f – female, m – male, 
HDL – high-density lipoprotein, LDL – low-density lipoprotein, PAH – pulmonary arterial hypertension, SBP – 
systolic blood pressure, TG – triglycerides *the number of patients who had not used statins are as follows: in 
PAH group: 76 females and 36 males; in control group 1097 females and 1037 males.
Variable β coefficient (SE) P value
Age (years) 0.01 (0.09) 0.88
Sex (female = 0/male = 1) − 0.18 (0.08) 0.03
WHO-FC − 0.2 (0.08) 0.02
6-MWD 0.12 (0.09) 0.17
NT-proBNP − 0.09 (0.09) 0.35
AST − 0.09 (0.09) 0.32
ALT − 0.09 (0.09) 0.3
Creatinine − 0.07 (0.09) 0.38
PAH etiology 
 IPAH (yes = 1/no = 0) − 0.13 (0.09) 0.13
 CTD-PAH (yes = 1/no = 0) 0.12 (0.08) 0.16
 CHD-PAH (yes = 1/no = 0) 0.05 (0.09) 0.56
Hemodynamic data
 mPAP − 0.01 (0.09) 0.9
 CI − 0.03 (0.09) 0.69
 PVR − 0.05 (0.09) 0.59
 RAP − 0.18 (0.1) 0.06
Cardiovascular risk factors
 Diabetes (yes = 1/no = 0) 0.04 (0.09) 0.67
 Hypertension (yes = 1/no = 0) 0.04 (0.09) 0.65
 BMI 0.1 (0.09) 0.26
 HDL cholesterol 0.06 (0.09) 0.51
 Triglycerides 0.4 (0.08) < 0.0001
Treatment
 statins (yes = 1/no = 0) − 0.11 (0.08) 0.18
 baseline PAH therapy 0.06 (0.09) 0.45
Table 3.  Univariate linear regression associations between different variables and low-density cholesterol 
level in patients with pulmonary arterial hypertension (n = 140). 6-MWD – 6-minute walk distance, ALT – 
alanine aminotransferase, AST – aspartate aminotransferase, BMI – body mass index, CHD-PAH – pulmonary 
arterial hypertension associated with congenital heart disease, CI – cardiac index, CTD-PAH – pulmonary 
arterial hypertension associated with connective tissue disease, HDL-C – high density lipoprotein cholesterol, 
IPAH – idiopathic pulmonary arterial hypertension, mPAP – mean pulmonary arterial pressure, NT-proBNP – 
N-terminal pro-brain natriuretic peptide, PAH – pulmonary arterial hypertension, PVR – pulmonary vascular 
resistance, RAP – right atrial pressure, SE – standard error, WHO-FC – World Health Organization functional 
class.
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[standard error] = 0.46 [0.09], p < 0.001) and WHO-FC (β coefficient [standard error] = − 0.27 [0.09], p = 0.005). 
In a subgroup of 108 patients in whom high-sensitivity C-reactive protein (hsCRP) was available (patients 
recruited after January 2011) we found a significant correlation (r = − 0.24 and p = 0.01) between this marker 
and LDL-C level.
LDL-C for the prediction of death in PAH. In the PAH sample, 32 patients died after a median follow-up 
time of 3320–36 months. Spline analysis revealed the association between LDL-C levels and survival to be linear 
(Fig. 1), allowing to model LDL-C in this way. Lower LDL-C levels were significantly associated with all-cause 
mortality in univariable analysis (HR: 0.44 per 1 mmol/l, 95% CI: 0.26–0.74, p = 0.002, Table 4) and after 
hierarchical adjustment for risk factors (HR in fully-adjusted model: 0.18 per 1 mmol/l, 95% CI: 0.07–0.47, 
p < 0.001, Table 4). Similar results were found when only patients who did not use statins were analysed (HR in 
fully-adjusted model: HR = 0.19 per mmol/l, 95% CI = 0.06–0.46, p < 0.001).
LDL-C changes after treatment in CTEPH patients. The total CTEPH population in our registry 
consisted of 34 patients (14 males) aged 64.5 [52.0–71.0] years. They were in WHO FC II (n = 4), III (n = 28), 
and IV (n = 2) on presentation. Similar to the PAH group, the CTEPH patients had lower LDL-C levels than 
the age and sex-matched control patients from the NATPOL study (2.7 ± 0.7 mmol/l vs. 3.2 ± 1.1 mmol/l, 
p < 0.001). In 21 patients we had data on LDL-C and hemodynamics at baseline and follow-up. The reversed 
CTEPH (rCTEPH) group consisted of 11 patients (4 males) aged 47.0 [42.0–65.0] years, in whom by defini-
tion mPAP decreased at least by ≥ 10 mmHg and to < 30 mmHg. In this group mPAP decreased from 40[31–
50] to 23[19–27] mmHg; p = 0.015, pulmonary vascular resistance (PVR) from 8.7[2.5–11.5] to 2.6[2.1–5.3] 
WU, p = 0.015, right atrial pressure (RAP) from 6.5 [4–9] to 5[2–14] mmHg; p = 0.1, while cardiac index (CI) 
increased from 2.1 [1.7–2.5] to 2.5 [2.0–2.7]; p = 0.045. The nonreversed (nrCTEPH) group consisted of 10 
Figure 1. Association between low-density lipoprotein cholesterol (LDL-C) levels and relative hazard for 
death in patients with pulmonary arterial hypertension. 
HR (95% CI) per 1 mmol/l p
model 1 0.44 (0.26–0.74) 0.002
model 2 0.44 (0.26–0.74) 0.002
model 3 0.44 (0.26–0.74) 0.002
model 4 0.38 (0.22–0.68) 0.0009
model 5 0.18 (0.07–0.47) 0.0005
model 6 0.18 (0.07–0.47) 0.0005
Table 4.  Cox regression model for the association between low-density lipoprotein cholesterol and 
mortality. Model 1: unadjusted analysis. Model 2: analysis adjusted for age and sex. Model 3: analysis adjusted for 
age, sex, diabetes, body mass index (BMI), statin use, hypertension, smoking. Model 4: analysis adjusted for age, 
sex, diabetes, BMI, statin use, hypertension, smoking, high density lipoprotein cholesterol (HDL-C), triglycerides. 
Significant predictor of death were: low-density lipoprotein cholesterol (LDL-C) and HDL-C (0.24; 0.08–0.66). 
Model 5: Analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, HDL-C, triglycerides, 
World Health Organization functional class (WHO-FC), etiology of pulmonary arterial hypertension (PAH), 
PAH-specific treatment at the end of observation, N-terminal pro-brain natriuretic peptide (NT-proBNP), 
6-minute walk distance (6-MWD), right atrial pressure (RAP), pulmonary vascular resistance, cardiac index (CI). 
Significant predictors of death were: LDL-C and current smoking (6.8; 1.3–35.6), NT-proBNP (1.02; 1.01–1.03), 
RAP (1.12; 1.02–1.25). Model 6: Analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, 
HDL-C, triglycerides, WHO-FC, etiology of PAH, PAH-specific treatment at the end of observation, NT-proBNP, 
6-MWD, RAP, mean pulmonary artery pressure, CI. Significant predictors of death were: LDL-C and current 
smoking (6.8; 1.3–35.6), NT-proBNP (1.02; 1.01–1.03), RAP (1.12; 1.02–1.25).
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patients (5 males) aged 66.0 [61.0–77.0] years in whom by definition there was no significant decrease of mPAP 
during observation. In this group hemodynamic parameters were similar at baseline and at follow-up (mPAP 
50.5[46–56] vs 47[43–51] mmHg; p = 0.85, PVR 13.5[13.0–14.7] vs 13.1 [10.7–13.7] WU; p = 0.80, RAP 3[1–4] 
vs 5[2–14] mmHg; p = 1.0, CI 1.8[1.7–1.9] vs 1.9[1.7–2.3] l/min/m2; p = 1.0).
rCTEPH patients were treated with pulmonary endarterectomy (PEA, n = 4) or balloon pulmonary angi-
oplasty (BPA, 5.0 [2.0–7.0] sessions per patient; n = 7) while nrCTEPH patients had monotherapy with rioc-
iguat (n = 1), sildenafil (n = 2), subcutaneous treprostinil (n = 1), one BPA session (n = 3), or a combination 
of sildenafil and subcutaneous treprostinil (n = 2) or subcutaneous treprostinil and one BPA session (n = 1). 
Follow-up time was similar in the rCTEPH and nrCTEPH group (12 [7–30] vs 18 [11–25] months, p = 0.5). 
During this time LDL-C increased from 2.6 [2.1–3.2] to 4.0 [2.8–4.9] mmol/l; p = 0.045 in the rCTEPH group, 
but remained unchanged in nrCTEPH patients: 2.4 mmol/l [2.2–2.7] vs 2.3 mmol/l [2.1–2.5], p = 1.0 (Fig. 2).
Discussion
In the present study we show that PAH patients have decreased LDL-C levels, and that low LDL-C levels are asso-
ciated with increased risk of all-cause mortality. Furthermore, we demonstrate that in CTEPH patients significant 
improvement of hemodynamic parameters is associated with reversal of decreased LDL-C levels.
Metabolic changes as reflected by decreased levels of HDL-C and increased insulin resistance have been 
described previously in the PAH population4–7. Low HDL-C in PAH patients has been associated with worse 
clinical outcomes and higher mortality. This finding was independent from cardiovascular risk factors, insulin 
resistance and severity of the disease. This phenomenon may be explained by antiinflammatory properties of 
HDL-C, its ability to enhance prostacyclin half-life and its protective role in endothelial dysfunction.
The phenomenon of reduced LDL-C levels has already been described in other chronic diseases such as 
rheumatoid arthritis12, cancer20, end-stage renal failure11 or chronic heart failure21 however, to the best of our 
knowledge this is the first study reporting changes in LDL-C levels and their prognostic role in PAH patients. 
Potential explanations for these findings include a chronic inflammatory state22, malnutrition18, and altered liver 
metabolism17.
Inflammatory cytokines are able to activate the reticuloendothelial system leading to enhanced 
receptor-independent clearance of LDL-C23. Conversely, suppression of the reticuloendothelial system leads to 
inhibition of LDL-C clearance24. Studies in rheumatoid arthritis have shown that suppression of inflammation 
with disease-modifying antirheumatic drugs or biological agents which target specific proinflammatory cytokines 
was accompanied by an increase in total cholesterol and LDL-C levels25,26. What is more, this increase was able 
to differentiate responders from non-responders to antirheumatic therapies27. An expanding body of knowl-
edge suggests that inflammation and altered immune processes underlie both development and progression of 
PAH14,28. In fact we found a significant correlation between hsCRP and LDL-C in subgroup analysis of our PAH 
patients. However further studies are needed to fully understand the relationship between inflammation and lipid 
profile in this group.
As the liver plays a central role in lipid metabolism controlling both production and clearance of serum 
lipoproteins it seems likely that its dysfunction could contribute to altered LDL-C levels in PAH. Right heart 
dysfunction can lead to congestive hepatopathy, which is related to right atrial pressure and the degree of tri-
cuspid regurgitation17. In fact, in our study we demonstrated that significant improvement of pulmonary hemo-
dynamics in CTEPH patients was associated with normalization of LDL-C plasma levels. However, the exact 
Figure 2. Low-density lipoprotein cholesterol (LDL-C) levels at baseline and follow-up in the reversed 
(rCTEPH) and non-reversed chronic thromboembolic pulmonary hypertension (nrCTEPH) patients. 
*p = 0.6 for the comparison of baseline data between rCTEPH and nrCTEPH group, **p = 0.005 for the 
comparison of follow-up data between rCTEPH and nrCTEPH group.
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pathophysiological pathways involved still need to be identified, since LDL-C normalization might not only be a 
direct consequence of hemodynamic improvement but also may result from improvement of the general condi-
tion of the patient29,30.
Low LDL-C levels have also been found in malnourished patients with chronic heart failure9. Accordingly, 
malnutrition could also contribute to the observed reduction of LDL-C in PAH patients. However, in our cohort 
none of the available markers of malnutrition such as body mass index (BMI) were associated with LDL-C level.
Several concomitant disorders and lifestyle interventions can influence LDL-C level31. Dietary changes, 
reduction of excessive body weight and increase in habitual physical activity may lead to lowering LDL-C con-
centration32. However we do not think that these lifestyle factors had significant impact on LDL-C level in our 
population. First, no specific recommendations on dietary patterns or weight reduction has been given to patients 
due to lack of scientific evidence. Second, the ability to increase of physical activity is limited in PAH patients due 
to exertional dyspnea. Third, most of our patients were within reference values for BMI and we did not find any 
correlation between LDL-C and BMI. Renal or hepatic impairment as well as thyroid abnormalities can also influ-
ence LDL-C level. In our patients, however, we did not find any associations between markers of these disorders 
(ALT, AST, creatinine) and LDL-C level. Thyroid abnormalities when present were well controlled. An important 
modulator of LDL-C concentration is the use of statins. Therefore, when we compared LDL-C levels to controls 
we analyzed separately all PAH patients and PAH patients who did not use statins. In both comparisons LDL-C 
levels were significantly decreased in PAH group. We monitored the use of statins at follow-up and did not find 
significant change in the number of patients who used these drugs as well as doses of statins in individual patients. 
In multivariable analysis we considered the use of statins as a potential confounder.
Our study suggests that traditional interpretation of hypercholesterolemia as a risk factor for increased mor-
tality may not apply in PAH population. Instead, our finding of the deleterious signal of low LDL-C levels in PAH 
corresponds with the concept of cholesterol paradox and reverse epidemiology whereby lower levels of traditional 
risk factors are associated with worse prognosis22. The evidence of a survival advantage associated with higher 
cholesterol levels has been provided for several populations with debilitating disorders such as heart failure9, 
rheumatoid arthritis12, acute myocardial infarction33,34 and in the elderly35,36.
The mechanism of interaction between LDL-C and clinical outcome has not been investigated in PAH. In 
other populations the importance of lipoproteins in down-regulation of the inflammatory immune response9 
and prevention of malnutrition18 has been claimed. Lipids and lipoproteins can modulate inflammatory mark-
ers22,37–40. Cholesterol can bind and neutralize endotoxin and liposaccharide components of infectious agents, 
thereby down-regulating the inflammatory state, which has been linked to progression of PAH14,28,41. Other data 
from experimental studies suggest that the effects of LDL-cholesterol on the arterial wall may be different in the 
pulmonary and systemic circulation. In rabbits, it has been demonstrated that hypercholesterolemia can increase 
pulmonary artery relaxation in response to methacholine42. Another experimental study43 in rats with monocro-
taline induced PAH showed that high-fat diet and hypercholesterolemia was associated with better prognosis as 
compared with standard diet. We have recently shown that low LDL-C levels, together with BMI < 25 kg/m2 and 
higher pulmonary artery pressure are independent determinants of increased pulmonary artery stiffness and 
together explain most of the variation in pulmonary artery pulse wave velocity16. The different role of LDL-C in 
pulmonary circulation disease compared to the systemic circulation could also have contributed to the negative 
results of studies with statins in PAH patients44.
Our data suggests a strong linear relationship between LDL-C levels and mortality with a 2- to 5-fold increase 
in risk of death for every 1 mmol/l decrease in LDL-C. We cannot exclude the possibility that low LDL-C do not 
have any direct pathophysiologic connection to mortality and is only a consequence of the severity of PAH or 
malnutrition, which are also associated with poor survival. However, LDL-C levels were associate with all-cause 
mortality independently from markers of PAH severity – WHO FC and malnutrition - low BMI. Therefore, our 
data suggests that the prognostic impact of LDL-C in PAH cannot be fully explained by PAH severity or malnu-
trition, thereby supporting its potential role as an independent risk marker in PAH. Nevertheless, whether low 
LDL-C levels represent a modifiable risk marker in PAH or just an epiphenomenon with no direct pathophysio-
logical impact on prognosis still needs to be elaborated.
Our study has several limitations. First, our data cannot provide explanations on the mechanisms by which 
low LDL-C levels influence survival in PAH patients. However, some plausible hypotheses can be proposed from 
our data for further studies. Second, as this is an observational study, we cannot establish a cause-and-effect rela-
tionship between LDL-C and outcome. Third, we could not ascertain the cause of death and compare the impact 
of low LDL-C on cardiovascular versus non-cardiovascular mortality or cardiovascular morbidity. Additionally 
we did not assess specifically dietary patterns of our patients which could have influenced LDL-C level. We also 
have not given the patients any specific advice on nutrition. This was mainly due to the fact that currently there is 
no evidence on the proper diet in patients with PAH.
Our study has several important strengths. First, the findings of LDL-C level alterations in the PAH population 
and their prognostic importance are novel and have not been previously reported. Second, as a control group we 
used a large representative sample of adults. Third, by using interventional and surgical treatment of CTEPH as a 
model for reliable, rapid improvement of hemodynamics, we could elaborate the dynamic relationship between 
LDL-C levels and severity of pulmonary hypertension beyond simple associations at baseline.
In summary, LDL-C levels are low in patients with PAH and are associated with an increased risk of death. 
Reversal of pulmonary hypertension in CTEPH patients increases low LDL-C levels. Future studies are necessary 
to gain more insights into the underlying pathophysiology of these findings and their role in the management of 
PAH.
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Methods
Patient population. Consecutive patients were recruited from the PH Program at the John Paul II Hospital 
(Krakow, Poland) between February 2009 and January 2015. Adult patients diagnosed with PAH except portopul-
monary PAH were eligible for the study. PH was defined as an increase in mPAP ≥ 25 mmHg at rest as assessed by 
right heart catheterization3. PAH was defined as precapillary PH (pulmonary artery wedge pressure ≤ 15 mmHg) 
with PVR > 3 Wood units in the absence of other causes of precapillary PH such as lung diseases, CTEPH or other 
rare diseases3. As a control group we chose a representative sample of 2413 Polish residents aged 18–79 years from 
the NATPOL 2011 Survey, a cross-sectional observational study aimed to assess the prevalence and control of 
cardiovascular disease risk factors in Poland45. All-cause mortality was ascertained by data collection from the 
Department of Nationals’ and Foreigners’ Affairs and through phone follow-up. The observation period started 
at the first assessment of the patient in our center and extended until January 2016. We also studied patients with 
CTEPH from our centre to see whether PH reversal can change LDL-C levels. For this purpose, we formed two 
subgroups to be compared: CTEPH patients with a significant hemodynamic improvement (rCTEPH) by inter-
ventional (BPA), surgical (PEA) or drug treatment. The second subgroup included CTEPH patients not meeting 
our definition of hemodynamic improvement (nrCTEPH). Significant hemodynamic improvement was defined 
as a reduction of mPAP by ≥ 10 mmHg and to < 30 mmHg. This analysis was performed only in patients without 
changes in statin therapy from 3 months before baseline until follow-up. CTEPH was defined as precapillary PH 
characterized by mismatched perfusion defects on lung scan and specific diagnostic signs for CTEPH seen by 
conventional pulmonary cineangiography. The diagnosis of CTEPH could have been established only after at 
least 3 months of effective anticoagulation3. The institutional ethics committee (Komisja Bioetyczna - Okregowa 
Izba Lekarska w Krakowie) approved the registry of patients with PAH and CTEPH in our center and the patients 
signed the informed consent. The study protocol conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki.
Clinical assessment and laboratory measurements. Clinical assessment, laboratory measurements 
and hemodynamic evaluation were made at the first evaluation of a patient in our center. Clinical assessment 
included demographic information, patient’s history, calculation of BMI, measurement of blood pressure, and 
N-terminal pro-brain natriuretic peptide (NT-proBNP) level, six minute walk test and assessment of the WHO 
FC, as well as other tests routinely performed at first evaluation of a PAH patient in our center but not analyzed in 
the study such as echocardiography. Obesity was defined as BMI ≥ 30 kg/m2, and overweight as BMI ≥ 25 kg/m2 
and < 30 kg/m2 46. Hypertension was diagnosed in patients with elevated systolic or diastolic blood pressure (BP) 
≥ 140 or 90 mmHg, respectively or patients having been prescribed a BP-lowering drugs for high BP. On the con-
trary patients were not classified as hypertensives when they were assuming drugs with BP-lowering effect but 
prescribed for other reasons than hypertension, e.g. for angina47. Diabetes was diagnosed based on the plasma 
glucose criteria of the American Diabetes Association, either the fasting plasma glucose or the 2-h plasma glucose 
value after a 75-g oral glucose tolerance test48. Active smoker was defined as having smoked at least for 1 month 
during the previous 12 months; all others were classified as nonsmokers16. Peripheral venous blood was drawn 
after overnight fast in all patients (PAH and CTEPH group) on the day of right heart catheterization. Plasma 
lipids were measured twice in every patient. In the PAH group measurements were performed at enrollment and 
three months after enrollment while in the CTEPH group before starting therapy and after at least three months 
of therapy. Blood chemistry was performed using the Cobas® 6000 analyzer (Roche Diagnostics International 
Ltd). LDL-C, HDL-C, and TG plasma concentrations were measured directly by using colorimetric technique 
with PEG-esterase, PEG-oxidase and peroxidase for HDL-C and LDL-C, and with lipase and peroxidase for TG 
concentrations. AST and ALT assay was performed accordingly to International Federation of Clinical Chemistry 
and Laboratory Medicine recommendations without pyridoxal phosphate activation. hsCRP was assessed using 
high sensitive latex assay. Creatinine level was assessed using kinetic colorimetric assay. Hemodynamic evaluation 
was performed during right heart catheterization using a Swan-Ganz-Catheter. Cardiac output was assessed using 
the oxygen consumption method. Clinical assessment and laboratory measurements performed in the NATPOL 
survey control group were described in detail elsewhere45.
Statistical analysis. Continuous variables were reported as mean ± standard deviation or as median (inter-
quartile range) and categorical variables as counts and percentages. For the comparison of continuous variables 
between two groups we used Student’s t-test or Mann-Whitney U-test as appropriate and for categorical variables 
the chi-squared test. The Wilcoxon rank sum test was used for paired comparisons of continuous parameters 
assessed at baseline and at follow-up. For the comparison of LDL-C levels in three different groups of patients 
with PAH we used the Kruskal-Wallis test.
To compare patients with controls, the groups were matched for age separately in males and females. Multiple 
regression analysis using forward stepwise selection was used to assess significant associations between patients’ 
characteristics and LDL-C levels. To exclude possible multicollinearity, we used multicollinearity diagnostic sta-
tistics and examined the variance inflation factor.
To assess the relationship between LDL-C and the risk of all-cause mortality, we used Cox proportional haz-
ards regression. To allow for flexible modeling of the association and account for potential non-linearity, we 
modeled LDL-C using restricted cubic splines.
Models were hierarchically adjusted for major cardiovascular risk factors and markers of severity of PAH: 
model 1 - unadjusted analysis; model 2: adjusted for age and sex; model 3: adjusted additionally for diabetes, 
BMI, statin use, hypertension, smoking; model 4 - adjusted additionally for HDL-C, TG; model 5 - adjusted addi-
tionally for WHO-FC, etiology of PAH, PAH-specific treatment at the end of observation, NT-proBNP, 6-minute 
walk distance, RAP, PVR, CI; model 6 - similar to model 5 but PVR was substituted with mPAP. Sample size was 
calculated for the comparison of LDL-C between the rCTEPH and nrCTEPH at follow-up. We expected that in 
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the rCTEPH group the LDL-C level would increase to the values of control group and that in the nrCTEPH group 
LDL-C would not change. Consequently, we expected that the difference of mean LDL-C between nrCTEPH 
group and rCTEPH group at follow-up would be 0.74 mmol/l. For alpha level of 0.05 and beta level of 0.2 the min-
imal number of patients in each group was 10. When comparing several parameters in the CTEPH group before 
and after treatment adjustment for multiple comparisons has been done. The significance level was set at alpha 
level of 0.05. Statistical analysis was performed with Statistica PL software [StatSoft, Inc. (2010). STATISTICA 
(data analysis software system), version 9.1. Tulsa, USA www.statsoft.com] and MedCalc version 11.6.1.0 
(MedCalc Software, Mariakerke, Belgium) and STATA. 14.1 (StataCorp).
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